No­vavax says up­dat­ed Covid-19 jab works against two sub­vari­ants; Ul­ti­movacs re­vis­es PhII can­cer vac­cine read­out

No­vavax said that its up­dat­ed XBB-tar­get­ing Covid-19 vac­cine showed neu­tral­iz­ing an­ti­body re­sponse to­ward XBB sub­vari­ants EG.5.1 and XBB.1.16.6.

The ex­act specifics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER